<DOC>
	<DOCNO>NCT00545337</DOCNO>
	<brief_summary>To evaluate efficacy ( term change HbA1c baseline endpoint ) safety ( term adverse event , clinical chemistry , lipid , hematology ) insulin glulisine ( HMR 1964 ) subject type I diabetes mellitus</brief_summary>
	<brief_title>Glulisine + Lantus Type I Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>type I diabetes mellitus ( onset diabetes age 40 ) , HbA1c range &gt; 6.5 &lt; 11 % , multiple injection regimen ( 1 year continuous insulin treatment ) , body mass index &lt; 35 . Active proliferative diabetic retinopathy , Diabetes type I diabetes mellitus , Pancreatectomised subject , Subjects undergone pancreas islet cell transplant , Requiring treatment permit drug study , Previous treatment ( period le 1 month begin trial ) insulin glargine , Hypersensitivity insulin , Major systemic disease , Impaired hepatic renal function The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>